ANNA MALOVANNAYA to Leukemia, Myeloid, Acute
This is a "connection" page, showing publications ANNA MALOVANNAYA has written about Leukemia, Myeloid, Acute.
Connection Strength
0.451
-
BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML. Leukemia. 2026 Feb; 40(2):304-313.
Score: 0.159
-
Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML. Blood. 2025 02 06; 145(6):612-624.
Score: 0.150
-
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor. Blood. 2024 05 16; 143(20):2059-2072.
Score: 0.142